Striatal and Extrastriatal Dopamine D2/D3 Receptors in Schizophrenia Evaluated With [18F]fallypride Positron Emission Tomography
- 1 October 2010
- journal article
- Published by Elsevier in Biological Psychiatry
- Vol. 68 (7) , 634-641
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (1P50MH066171)
- Amgen
- Pfizer
- Intra-Cellular Therapies
- Pfizer
- GlaxoSmithKline
This publication has 52 references indexed in Scilit:
- Hippocampal Gamma Oscillations Increase with Memory LoadThe Journal of Neuroscience, 2010
- Striatal and extrastriatal dopamine release measured with PET and [18F] fallyprideSynapse, 2009
- Dopamine D2 Receptor Levels in Striatum, Thalamus, Substantia Nigra, Limbic Regions, and Cortex in Schizophrenic SubjectsBiological Psychiatry, 2009
- The Anatomy of First-Episode and Chronic Schizophrenia: An Anatomical Likelihood Estimation Meta-AnalysisAmerican Journal of Psychiatry, 2008
- Design and Implementation of an Automated Partial Volume Correction in PET: Application to Dopamine Receptor Quantification in the Normal Human StriatumJournal of Nuclear Medicine, 2008
- Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: Prospective data from phase 1Schizophrenia Research, 2008
- Consensus Nomenclature for in vivo Imaging of Reversibly Binding RadioligandsJournal of Cerebral Blood Flow & Metabolism, 2007
- Low Dopamine D2Receptor Binding in Subregions of the Thalamus in SchizophreniaAmerican Journal of Psychiatry, 2004
- MR-Based Correction of Brain PET Measurements for Heterogeneous Gray Matter Radioactivity DistributionJournal of Cerebral Blood Flow & Metabolism, 1996
- Fluorinated benzamide neuroleptics—III. Development of (S)-N-[(1-allyl-2-pyrrolidinyl)methyl]-5-(3-[18F]fluoropropyl)-2,3-dimethoxybenzamide as an improved dopamine D-2 receptor tracerNuclear Medicine and Biology, 1995